\documentclass[11pt,twoside]{article}\makeatletter

\IfFileExists{xcolor.sty}%
  {\RequirePackage{xcolor}}%
  {\RequirePackage{color}}
\usepackage{colortbl}
\usepackage{wrapfig}
\usepackage{ifxetex}
\ifxetex
  \usepackage{fontspec}
  \usepackage{xunicode}
  \catcode`⃥=\active \def⃥{\textbackslash}
  \catcode`❴=\active \def❴{\{}
  \catcode`❵=\active \def❵{\}}
  \def\textJapanese{\fontspec{Noto Sans CJK JP}}
  \def\textChinese{\fontspec{Noto Sans CJK SC}}
  \def\textKorean{\fontspec{Noto Sans CJK KR}}
  \setmonofont{DejaVu Sans Mono}
  
\else
  \IfFileExists{utf8x.def}%
   {\usepackage[utf8x]{inputenc}
      \PrerenderUnicode{–}
    }%
   {\usepackage[utf8]{inputenc}}
  \usepackage[english]{babel}
  \usepackage[T1]{fontenc}
  \usepackage{float}
  \usepackage[]{ucs}
  \uc@dclc{8421}{default}{\textbackslash }
  \uc@dclc{10100}{default}{\{}
  \uc@dclc{10101}{default}{\}}
  \uc@dclc{8491}{default}{\AA{}}
  \uc@dclc{8239}{default}{\,}
  \uc@dclc{20154}{default}{ }
  \uc@dclc{10148}{default}{>}
  \def\textschwa{\rotatebox{-90}{e}}
  \def\textJapanese{}
  \def\textChinese{}
  \IfFileExists{tipa.sty}{\usepackage{tipa}}{}
\fi
\def\exampleFont{\ttfamily\small}
\DeclareTextSymbol{\textpi}{OML}{25}
\usepackage{relsize}
\RequirePackage{array}
\def\@testpach{\@chclass
 \ifnum \@lastchclass=6 \@ne \@chnum \@ne \else
  \ifnum \@lastchclass=7 5 \else
   \ifnum \@lastchclass=8 \tw@ \else
    \ifnum \@lastchclass=9 \thr@@
   \else \z@
   \ifnum \@lastchclass = 10 \else
   \edef\@nextchar{\expandafter\string\@nextchar}%
   \@chnum
   \if \@nextchar c\z@ \else
    \if \@nextchar l\@ne \else
     \if \@nextchar r\tw@ \else
   \z@ \@chclass
   \if\@nextchar |\@ne \else
    \if \@nextchar !6 \else
     \if \@nextchar @7 \else
      \if \@nextchar (8 \else
       \if \@nextchar )9 \else
  10
  \@chnum
  \if \@nextchar m\thr@@\else
   \if \@nextchar p4 \else
    \if \@nextchar b5 \else
   \z@ \@chclass \z@ \@preamerr \z@ \fi \fi \fi \fi
   \fi \fi  \fi  \fi  \fi  \fi  \fi \fi \fi \fi \fi \fi}
\gdef\arraybackslash{\let\\=\@arraycr}
\def\@textsubscript#1{{\m@th\ensuremath{_{\mbox{\fontsize\sf@size\z@#1}}}}}
\def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}}
\def\abbr{}
\def\corr{}
\def\expan{}
\def\gap{}
\def\orig{}
\def\reg{}
\def\ref{}
\def\sic{}
\def\persName{}\def\name{}
\def\placeName{}
\def\orgName{}
\def\textcal#1{{\fontspec{Lucida Calligraphy}#1}}
\def\textgothic#1{{\fontspec{Lucida Blackletter}#1}}
\def\textlarge#1{{\large #1}}
\def\textoverbar#1{\ensuremath{\overline{#1}}}
\def\textquoted#1{‘#1’}
\def\textsmall#1{{\small #1}}
\def\textsubscript#1{\@textsubscript{\selectfont#1}}
\def\textxi{\ensuremath{\xi}}
\def\titlem{\itshape}
\newenvironment{biblfree}{}{\ifvmode\par\fi }
\newenvironment{bibl}{}{}
\newenvironment{byline}{\vskip6pt\itshape\fontsize{16pt}{18pt}\selectfont}{\par }
\newenvironment{citbibl}{}{\ifvmode\par\fi }
\newenvironment{docAuthor}{\ifvmode\vskip4pt\fontsize{16pt}{18pt}\selectfont\fi\itshape}{\ifvmode\par\fi }
\newenvironment{docDate}{}{\ifvmode\par\fi }
\newenvironment{docImprint}{\vskip 6pt}{\ifvmode\par\fi }
\newenvironment{docTitle}{\vskip6pt\bfseries\fontsize{22pt}{25pt}\selectfont}{\par }
\newenvironment{msHead}{\vskip 6pt}{\par}
\newenvironment{msItem}{\vskip 6pt}{\par}
\newenvironment{rubric}{}{}
\newenvironment{titlePart}{}{\par }

\newcolumntype{L}[1]{){\raggedright\arraybackslash}p{#1}}
\newcolumntype{C}[1]{){\centering\arraybackslash}p{#1}}
\newcolumntype{R}[1]{){\raggedleft\arraybackslash}p{#1}}
\newcolumntype{P}[1]{){\arraybackslash}p{#1}}
\newcolumntype{B}[1]{){\arraybackslash}b{#1}}
\newcolumntype{M}[1]{){\arraybackslash}m{#1}}
\definecolor{label}{gray}{0.75}
\def\unusedattribute#1{\sout{\textcolor{label}{#1}}}
\DeclareRobustCommand*{\xref}{\hyper@normalise\xref@}
\def\xref@#1#2{\hyper@linkurl{#2}{#1}}
\begingroup
\catcode`\_=\active
\gdef_#1{\ensuremath{\sb{\mathrm{#1}}}}
\endgroup
\mathcode`\_=\string"8000
\catcode`\_=12\relax

\usepackage[a4paper,twoside,lmargin=1in,rmargin=1in,tmargin=1in,bmargin=1in,marginparwidth=0.75in]{geometry}
\usepackage{framed}

\definecolor{shadecolor}{gray}{0.95}
\usepackage{longtable}
\usepackage[normalem]{ulem}
\usepackage{fancyvrb}
\usepackage{fancyhdr}
\usepackage{graphicx}
\usepackage{marginnote}

\renewcommand{\@cite}[1]{#1}


\renewcommand*{\marginfont}{\itshape\footnotesize}

\def\Gin@extensions{.pdf,.png,.jpg,.mps,.tif}

  \pagestyle{fancy}

\usepackage[pdftitle={Vitamin D Status of Sudanese Children with Sickle Cell Anemia},
 pdfauthor={}]{hyperref}
\hyperbaseurl{}

	 \paperwidth210mm
	 \paperheight297mm
              
\def\@pnumwidth{1.55em}
\def\@tocrmarg {2.55em}
\def\@dotsep{4.5}
\setcounter{tocdepth}{3}
\clubpenalty=8000
\emergencystretch 3em
\hbadness=4000
\hyphenpenalty=400
\pretolerance=750
\tolerance=2000
\vbadness=4000
\widowpenalty=10000

\renewcommand\section{\@startsection {section}{1}{\z@}%
     {-1.75ex \@plus -0.5ex \@minus -.2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\Large\bfseries}}
\renewcommand\subsection{\@startsection{subsection}{2}{\z@}%
     {-1.75ex\@plus -0.5ex \@minus- .2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\Large}}
\renewcommand\subsubsection{\@startsection{subsubsection}{3}{\z@}%
     {-1.5ex\@plus -0.35ex \@minus -.2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\large}}
\renewcommand\paragraph{\@startsection{paragraph}{4}{\z@}%
     {-1ex \@plus-0.35ex \@minus -0.2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\normalsize}}
\renewcommand\subparagraph{\@startsection{subparagraph}{5}{\parindent}%
     {1.5ex \@plus1ex \@minus .2ex}%
     {-1em}%
     {\reset@font\normalsize\bfseries}}


\def\l@section#1#2{\addpenalty{\@secpenalty} \addvspace{1.0em plus 1pt}
 \@tempdima 1.5em \begingroup
 \parindent \z@ \rightskip \@pnumwidth 
 \parfillskip -\@pnumwidth 
 \bfseries \leavevmode #1\hfil \hbox to\@pnumwidth{\hss #2}\par
 \endgroup}
\def\l@subsection{\@dottedtocline{2}{1.5em}{2.3em}}
\def\l@subsubsection{\@dottedtocline{3}{3.8em}{3.2em}}
\def\l@paragraph{\@dottedtocline{4}{7.0em}{4.1em}}
\def\l@subparagraph{\@dottedtocline{5}{10em}{5em}}
\@ifundefined{c@section}{\newcounter{section}}{}
\@ifundefined{c@chapter}{\newcounter{chapter}}{}
\newif\if@mainmatter 
\@mainmattertrue
\def\chaptername{Chapter}
\def\frontmatter{%
  \pagenumbering{roman}
  \def\thechapter{\@roman\c@chapter}
  \def\theHchapter{\roman{chapter}}
  \def\thesection{\@roman\c@section}
  \def\theHsection{\roman{section}}
  \def\@chapapp{}%
}
\def\mainmatter{%
  \cleardoublepage
  \def\thechapter{\@arabic\c@chapter}
  \setcounter{chapter}{0}
  \setcounter{section}{0}
  \pagenumbering{arabic}
  \setcounter{secnumdepth}{6}
  \def\@chapapp{\chaptername}%
  \def\theHchapter{\arabic{chapter}}
  \def\thesection{\@arabic\c@section}
  \def\theHsection{\arabic{section}}
}
\def\backmatter{%
  \cleardoublepage
  \setcounter{chapter}{0}
  \setcounter{section}{0}
  \setcounter{secnumdepth}{2}
  \def\@chapapp{\appendixname}%
  \def\thechapter{\@Alph\c@chapter}
  \def\theHchapter{\Alph{chapter}}
  \appendix
}
\newenvironment{bibitemlist}[1]{%
   \list{\@biblabel{\@arabic\c@enumiv}}%
       {\settowidth\labelwidth{\@biblabel{#1}}%
        \leftmargin\labelwidth
        \advance\leftmargin\labelsep
        \@openbib@code
        \usecounter{enumiv}%
        \let\p@enumiv\@empty
        \renewcommand\theenumiv{\@arabic\c@enumiv}%
	}%
  \sloppy
  \clubpenalty4000
  \@clubpenalty \clubpenalty
  \widowpenalty4000%
  \sfcode`\.\@m}%
  {\def\@noitemerr
    {\@latex@warning{Empty `bibitemlist' environment}}%
    \endlist}

\def\tableofcontents{\section*{\contentsname}\@starttoc{toc}}
\parskip0pt
\parindent1em
\def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}}
\newenvironment{reflist}{%
  \begin{raggedright}\begin{list}{}
  {%
   \setlength{\topsep}{0pt}%
   \setlength{\rightmargin}{0.25in}%
   \setlength{\itemsep}{0pt}%
   \setlength{\itemindent}{0pt}%
   \setlength{\parskip}{0pt}%
   \setlength{\parsep}{2pt}%
   \def\makelabel##1{\itshape ##1}}%
  }
  {\end{list}\end{raggedright}}
\newenvironment{sansreflist}{%
  \begin{raggedright}\begin{list}{}
  {%
   \setlength{\topsep}{0pt}%
   \setlength{\rightmargin}{0.25in}%
   \setlength{\itemindent}{0pt}%
   \setlength{\parskip}{0pt}%
   \setlength{\itemsep}{0pt}%
   \setlength{\parsep}{2pt}%
   \def\makelabel##1{\upshape ##1}}%
  }
  {\end{list}\end{raggedright}}
\newenvironment{specHead}[2]%
 {\vspace{20pt}\hrule\vspace{10pt}%
  \phantomsection\label{#1}\markright{#2}%

  \pdfbookmark[2]{#2}{#1}%
  \hspace{-0.75in}{\bfseries\fontsize{16pt}{18pt}\selectfont#2}%
  }{}
      \def\TheFullDate{2018-01-15 (revised: 15 January 2018)}
\def\TheID{\makeatother }
\def\TheDate{2018-01-15}
\title{Vitamin D Status of Sudanese Children with Sickle Cell Anemia}
\author{}\makeatletter 
\makeatletter
\newcommand*{\cleartoleftpage}{%
  \clearpage
    \if@twoside
    \ifodd\c@page
      \hbox{}\newpage
      \if@twocolumn
        \hbox{}\newpage
      \fi
    \fi
  \fi
}
\makeatother
\makeatletter
\thispagestyle{empty}
\markright{\@title}\markboth{\@title}{\@author}
\renewcommand\small{\@setfontsize\small{9pt}{11pt}\abovedisplayskip 8.5\p@ plus3\p@ minus4\p@
\belowdisplayskip \abovedisplayskip
\abovedisplayshortskip \z@ plus2\p@
\belowdisplayshortskip 4\p@ plus2\p@ minus2\p@
\def\@listi{\leftmargin\leftmargini
               \topsep 2\p@ plus1\p@ minus1\p@
               \parsep 2\p@ plus\p@ minus\p@
               \itemsep 1pt}
}
\makeatother
\fvset{frame=single,numberblanklines=false,xleftmargin=5mm,xrightmargin=5mm}
\fancyhf{} 
\setlength{\headheight}{14pt}
\fancyhead[LE]{\bfseries\leftmark} 
\fancyhead[RO]{\bfseries\rightmark} 
\fancyfoot[RO]{}
\fancyfoot[CO]{\thepage}
\fancyfoot[LO]{\TheID}
\fancyfoot[LE]{}
\fancyfoot[CE]{\thepage}
\fancyfoot[RE]{\TheID}
\hypersetup{citebordercolor=0.75 0.75 0.75,linkbordercolor=0.75 0.75 0.75,urlbordercolor=0.75 0.75 0.75,bookmarksnumbered=true}
\fancypagestyle{plain}{\fancyhead{}\renewcommand{\headrulewidth}{0pt}}

\date{}
\usepackage{authblk}

\providecommand{\keywords}[1]
{
\footnotesize
  \textbf{\textit{Index terms---}} #1
}

\usepackage{graphicx,xcolor}
\definecolor{GJBlue}{HTML}{273B81}
\definecolor{GJLightBlue}{HTML}{0A9DD9}
\definecolor{GJMediumGrey}{HTML}{6D6E70}
\definecolor{GJLightGrey}{HTML}{929497} 

\renewenvironment{abstract}{%
   \setlength{\parindent}{0pt}\raggedright
   \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}}
   \vskip16pt
   \textcolor{GJBlue}{\large\bfseries\abstractname\space}
}{%   
   \vskip8pt
   \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}}
   \vskip16pt
}

\usepackage[absolute,overlay]{textpos}

\makeatother 
      \usepackage{lineno}
      \linenumbers
      
\begin{document}

             \author[1]{Fathelrahman  E.Ahmed}

             \author[2]{Manal A  Mohammed}

             \affil[1]{  Alneelain university}

\renewcommand\Authands{ and }

\date{\small \em Received: 7 December 2017 Accepted: 4 January 2018 Published: 15 January 2018}

\maketitle


\begin{abstract}
        


A low level of 25 hydroxy vitamin D (25 OHD) is seen more in children with sickle cell anemia (SCA) than healthy children. SCA is common in Sudan, but the status of vitamin D is unknown in Sudanese children with SCA. We aimed to determine the prevalence rate of low level of vitamin D in this population and its relation to the painful crisis, bonefracture, osteomyelitis and hemoglobin level and biochemical data.This was a prospective cross-sectional hospital-based study. Children with SCA age six months to 18 years who met the recruitment criteria made the study group, and sex and age-matched healthy children were the control group.There were 64 children in the study group and 21 in the control group. Low 25 OHD, low mean serum calcium, hypocalcemia and high serum alkaline phosphatase were significantly prevalent in the study group (P.0001, P.0001, P.0001, P.003) respectively. Painful crisis, bone fracture, osteomyelitis, and anemia were not increased in these patients.

\end{abstract}


\keywords{sickle cell anemia, 25 hydroxy vitamin d, calcium, alkaline phosphatase, bone fracture, osteomyelitis. body mass index, hemoglobin.}

\begin{textblock*}{18cm}(1cm,1cm) % {block width} (coords) 
\textcolor{GJBlue}{\LARGE Global Journals \LaTeX\ JournalKaleidoscope\texttrademark}
\end{textblock*}

\begin{textblock*}{18cm}(1.4cm,1.5cm) % {block width} (coords) 
\textcolor{GJBlue}{\footnotesize \\ Artificial Intelligence formulated this projection for compatibility purposes from the original article published at Global Journals. However, this technology is currently in beta. \emph{Therefore, kindly ignore odd layouts, missed formulae, text, tables, or figures.}}
\end{textblock*}


\let\tabcellsep& 	 	 		 
\section[{I. Introduction}]{I. Introduction}\par
ickle cell anemia (SCA), a heterogeneous disorder, is characterized by the presence of Hemoglobin S where Glutamic Acid is replaced by valine at position 6 of the beta globin chain. Its clinical manifestation includes chronic hemolysis, increased susceptibility to infection and vaso-occlusive crisis \hyperref[b0]{(1,}\hyperref[b1]{2)}. SCA is prevalent in Sudan, it ranges from 0.8\%-30.4\% depending on the geographical location \hyperref[b2]{(3)}.Khartoum, capital of Sudan, is a multiethnic town that contains almost all Sudanese tribes. Patients with SCA are mostly from the tribes (predominantly of African descent) that migrated from the West during the drought that struck the area in 1980 \hyperref[b2]{(3)}.\par
Children with sickle cell anemia are at higher risk of low 25 OHD level than healthy children. Approximately 65-100\% of children with SCA were found to have vitamin D deficiency \hyperref[b3]{(4)}. Black Americans were found to have Vitamin D insufficiency more than other Americans \hyperref[b4]{(5,}\hyperref[b5]{6)}. This is because pigmentation probably reduces vitamin D production in the skin \hyperref[b6]{(7)}.\par
Vitamin D deficiency is a serum level of 25 OHD below 20 ng/ml (50 nmmol/l), insufficiency is 25 OHD level 21-29 ng/ml (52.5-72.5 nmmol/l), while severe deficiency is level between 5-10 ng/ml, and it is very severe if less than 5 ng/ml \hyperref[b7]{(8)}.\par
We hypothesized that Sudanese children with SCA have low plasma 25 OHD level. This study aimed to determine vitamin D status in this population, to identify risk factors associated with low vitamin D level and to determine the relation between low serum vitamin D level and the frequency of bone pain, bone fracture and osteomyelitis. 
\section[{II. Patients and Method}]{II. Patients and Method}\par
This was a prospective Cross -sectional hospital-based study done in the outpatient clinics of a major pediatric hospital (Jafar Ibn Ouf children hospital) and a general teaching hospital (Ibrahim Malik) in Khartoum, Sudan from June 2013 to October 2013.\par
Study Population: Sudanese Children six months to 18 years old with a confirmed diagnosis of sickle cell anemia making the study group, age and sex-matched healthy children making the control group.\par
Children with liver disease, renal disease, chronic diarrhea, on vitamin D, oral calcium or had received blood transfusion in the past three months were excluded from the study. A questionnaire was used to collect data. It included: demographic data, number of admissions for painful crisis, number of blood transfusions, history of bone fracture, bone infection and 24hours dietary record. Hemoglobin level and hemoglobin electrophoresis were obtained from the patient medical records.5.5 ml of venous blood were drawn from each patient: 3.0ml were placed in a Lithium Heparin tube for 25OHD assay. Serum was separated and frozen at -20 degrees .Assay for 25OHD was performed after completion of sample collection using Tecanelisa machine (Tecan Trading AG, Switzerland). The remaining 2.5ml were put in a similar container for serum calcium, phosphate, and alkaline phosphatase measurement. These were assayed immediately using the U/V automation method using Bio system auto machine. We obtained a written informed consent from the patients or caregivers. Ethical approval was obtained from the Sudan medical specialization board and the hospitals ethical committees.\par
Were presented the results in the form of frequency, percentage and mean.  
\section[{Results}]{Results}\par
We enrolled 90 children in the study: 69 children with sickle cell anemia made the study group, and 21 healthy children were the control group. Five children were excluded from the study group (three were on calcium and vitamin D, and two were recently transfused with blood) leaving 64 children for analysis. All children were of the SS genotype. Patients characteristics are shown in Table \hyperref[b0]{(1)}. The mean serum 25 OHD level was significantly lower in the study group than in the control group Table \hyperref[b0]{(1)}. Low level of 25 OHD was found in 62.5 \% of the children in the study group, and 38 \% of children in the control group P (0.0001). Vitamin D deficiency was present in 18.8 \% of those with low vitamin D in the study group (Table \hyperref[tab_2]{2}). In the control group eight children (38 \%) had a low 25 OHD level (<30 ng/dl), all were having 25 OHD insufficiency. In children with SCA a low 25 OHD was present in 55\% of males and 45\% of females (P 0.340). The majority (80\%) of children with low 25 OHD (<30 ng/dl) level in the study group were 1-12 years old, and 91.6 \% (11/12) of children with 25 OHD deficiency were present within this age. The percentage of those with low vitamin D level increases with increasing age (Figure  {\ref 1}).  52 children were diagnosed to have SCA before the age of one year and 32 (61.5\%) of them had low 25 OHD. Twelve children were diagnosed to have SCA after the age of one year, and 8 (66.7\%) had low 25 OHD (P 0.929). 
\section[{Parameters}]{Parameters}\par
In the study group, the mean serum calcium was significantly lower in patients with SCA than control (8.5 ± 0.82 mg/dl vs. 8.8 ± 0.55 mg/dl P.0001). Hypocalcemia (Serum calcium below 8.6 mg/dl) occurred in 30 children in the study group (43.4\%), and none in the control group, and it developed more in children with low 25 OHD than in those with normal 25 OHD (70\% vs. 8.3\%) (P0.0001) Table \hyperref[b2]{(3)}. Frequent painful crises (? Five attacks per year) were experienced by 60 \% of children with low serum calcium compared to 48.8 \% of those with normal calcium (P 0.368). The mean serum alkaline phosphatase level was significantly higher in those with low 25 OHD level than those with a normal level (460 IU vs. 237 IU P.0.0001). An elevated serum alkaline phosphatase (>320 IU) was more frequent in children with low 25 ODH than in those with normal level (62.5\%\% vs. 12.5\% P value 0.030). High serum alkaline phosphatase level was not associated with frequent painful crises (37.5\% vs. 25\%P 0.883).\par
The mean serum phosphate in the study group was comparable to that in the control group (4.1 ± 0.89 meg/l vs. 3.95 ± 0.53meg/l P 0.28). Hypophosphatemia (serum phosphate level <2.5 mg/dl) was found in 9 (14.1\%) children with low 25 OHD but none in those with normal 25 OHD (p 0.280). All hypophosphatemic children were hypocalcemic.\par
Low 25 OHD level in the study group was not associated with lower hemoglobin level, the need for blood transfusion, more painful crises, increased bone fractures or osteomyelitis (Table \hyperref[tab_5]{4}). There were more children with BMI below the 3 rd percentile in the study group than the control group (67.2\% vs 33.3\% P 0.003). Within the study group, there was no difference in the BMI between those with low and normal 25 OHD level (62.5\% vs. 75\%) (P 0.108) Table \hyperref[b4]{(5)}.  
\section[{F}]{F}\par
Dietary intake of fish, meat, and milk, was comparable in the study group and the control group and within the study group (P value 0.117, 0.108) respectively.\par
In the study group, sun exposure for more than 15 minutes a day was comparable in those with low and normal 25 OHD (87.5\% vs. 87.5 \% P 0.163). 
\section[{IV. Discussion}]{IV. Discussion}\par
This is the first study in Sudan that determined vitamin D status in Sudanese children with sickle cell anemia .Like other studies we found a high prevalence of low 25 OHD level (62.5\%) with 70\% of them being deficient. Twelve studies reported vitamin D status in children and adolescent with sickle cell anemia (4, 9-20), four of them had used a definition similar to ours (10-13) Low vitamin D was present in 80-98\% of children included in three of these studies and 81.5-100 \% of them were deficient \hyperref[b9]{(10,}\hyperref[b10]{11,}\hyperref[b12]{13)}. These rates are higher than ours. The prevalence rate reported from Madrid, Spain (12), a sunny country like Sudan, is comparable to ours. We could explain this finding by the fact that our children had good sun exposure despite they had dark skin color: a factor that influences vitamin D synthesis. \hyperref[b20]{(21)} .\par
Males were more likely to have low 25OHD level than females although this was not statistically significant, a finding similar to that reported by Mohammed et al. \hyperref[b14]{(15)} Low 25OHD level was present from the age of one year throughout childhood. Its frequency increased with increasing age. A similar observation was reported in normal children \hyperref[b21]{(22)} as well as children with SCD (4, 9, 12). However, this effect of age on vitamin D status was not observed in studies from Kuwait and Saudi Arabia \hyperref[b9]{(10,}\hyperref[b14]{15)}.\par
We observed a tendency towards low serum calcium in the study group. A similar tendency was reported before in children and adults with sickle cell disease \hyperref[b14]{(15,}\hyperref[b22]{(23)}\hyperref[b23]{(24)}\hyperref[b24]{(25)}\hyperref[b25]{(26)}. This tendency was observed in the absence of low serum albumin \hyperref[b22]{(23)}. Hypocalcaemia was reported in 14 \% of Saudi patients with sickle cell disease: in the same study low vitamin D was present in 12\% of patients. We observed hypocalcaemia in almost half of our patients and the majority of them were those with low 25 OHD. Suggested causes of hypocalcemia include an increased activity of calcium magnesium ATPase \hyperref[b23]{(24,}\hyperref[b26]{27,}\hyperref[b28]{28)}, reduced intestinal calcium absorption, and impaired vitamin D synthesis . \hyperref[b14]{(15)} Low dietary intake of vitamin D was found to be significantly associated with lower serum vitamin D levels in both healthy children and children with HbSS. (4) However, this is not the case in this study as adequate sun exposure and adequate intake of diet rich in vitamin D was seen in our patients. This is similar to what was reported by others \hyperref[b14]{(15)}.\par
Low serum 25OHD causes high level of ALP \hyperref[b29]{(29)}. In this study low 25OHD level was found to be associated with significantly high ALP and low calcium level. High alkaline phosphatase was reported in Kuwaiti children who had SCA and 25 OHD deficiencies \hyperref[b9]{(10)}. However, normal calcium and alkaline phosphatase level \hyperref[b12]{(13)} or lack of association between ALP and 25 OHD level \hyperref[b11]{(12)} were reported in children with SCA. Serum ALP in SCA may be elevated due to bone destruction and vaso-occlusive crisis (VOC) and it is considered a sensitive marker of bone turn over \hyperref[b30]{(30)}. This is unlikely to be the case in this study as those patients with low 25OHD were in their steady state and had no more painful crisis than those with normal level of 25 OHD. Furthermore painful crises were found not to affect serum calcium level \hyperref[b22]{(23)}.\par
The status of serum phosphate in children with SCD was reported by few studies \hyperref[b11]{(12,}\hyperref[b22]{23,}\hyperref[b31]{31,}\hyperref[b32]{32)}. Elevated levels were reported by two studies \hyperref[b22]{(23,}\hyperref[b31]{31)}. One of these studies suggested resistance to the phosphaturic effect of fibroblast growth factor 23 (FGF23) to be the cause. (  {\ref 31}) Low serum phosphate level was reported by Al-harbi et al and that was attributed to elevated level of parathyroid growth hormone (PTH) \hyperref[b32]{(32)}. An inverse correlation between PTH and phosphorous level was observed by Garrido et al \hyperref[b11]{(12)}. In our study the serum phosphate level was normal in the majority of patients: however, 14\% were hypophosphatemic. We did not measure PTH in this study but others had reported high level of the hormone when vitamin D or serum calcium were low \hyperref[b14]{(15)} and all our patients with hypophosphatemia had hypocalcaemia. Thus, elevated levels of PTH could be the cause of low phosphate level in our patients. Therefore, in children with SCA elevated serum ALP, hypophosphatemia or hypocalcemia can be taken as a marker of low 25 OHD during steady state condition.\par
The significance of low 25 OHD and if there is a pathological association is hard to know. Our result did not suggest an association with increased painful episodes, as indicated by the number of pain episodes per year and number of hospital admissions due to pain. Similarly, two retrospective studies from America and the United Kingdom failed to demonstrate increased painful episodes with low 25 OHD \hyperref[b8]{(9,}\hyperref[b33]{33)}. Furthermore, Jackson etal did not find an increased rate of acute painful crisis or acute chest syndrome in 64\% of their patients despite the presence of severe vitamin D deficiency (<10 ng/ml) \hyperref[b24]{(25)}. But, Adegoke et al. and Lee et al. found a possible association between low serum vitamin D levels and increased frequency of acute pain episodes \hyperref[b34]{(34,}\hyperref[b36]{35)}. In a randomized controlled trial, six weeks of a high oral dose of vitamin D in children and adolescent with SCA and low vitamin D level reduced the number of pain days per week irrespective of baseline 25 OHD levels \hyperref[b15]{(16)}.\par
The overall incidence of bone fracture in this study (6.3\%) is not different from that in the control group. If we excluded those in whom fractures were © 2018 Global Journals F associated with osteomyelitis then the incidence will be comparable to that reported in healthy British children \hyperref[b37]{(36)}. Reports regarding the prevalence of bone fractures in children with SCA are limited. Bone fractures were reported in 18.8\% of Egyptian children, adolescent and young adults with SCA (37). Fung et al. reported a prevalence rate of 12.5\% of bone fractures in children with SCA age 12-18 years, with falls and recreational sport being the commonest predisposing factors \hyperref[b39]{(38)}. Four cases, including two with pathological fractures, were reported from Spain \hyperref[b11]{(12)}. One pathological vertebral fracture was detected in 97 Omani children with SCA \hyperref[b40]{(39 )}. The French Study Group on sickle cell disease reported the acute clinical events in 299 homozygous sickle cell patients (age 10.1+/-5.8 yrs.): there was no single case of bone fracture despite the presence of osteomyelitis in 12\% of the cohort \hyperref[b41]{(40)}.\par
A slight decrease in bone mineral density (BMD) was reported in children with SCA \hyperref[b11]{(12,}\hyperref[b38]{37,}\hyperref[b18]{19)}. Low BMD was not found to be associated with vitamin D deficiency \hyperref[b11]{(12,}\hyperref[b37]{36)} or calcium and ALP level \hyperref[b39]{(38)} .It is probably due to an abnormal bone formation \hyperref[b18]{(19)}.The relationship between low BMD and bone fractures was not evaluated in two studies that reported low BMD and bone fracture \hyperref[b11]{(12,}\hyperref[b38]{37)}. In African American children (non-SCD) with fracture of the forearm, 25 OHD insufficiency was present in 59\% of them, but all of them had normal BMD \hyperref[b42]{(41)}. BMD was not measured in this study. Despite a high prevalence rate of low vitamin D among our patients, the rate of bone fracture was similar to that in healthy children. Therefore, vitamin D insufficiency does not seem to predispose Sudanese children with SCA to bone fracture. Staphylococcus aureus, salmonella, Pseudomonas aeruginosa, Escherichia coli (E. coli) and klebsiella pneumonae are causative organisms of osteomyelitis in children \hyperref[b43]{(42,}\hyperref[b46]{43)}.Vitamin D3 was shown to have an inhibitory activity, in vitro, on strains of Streptococcus pyogenes, staphylococcus aureus, Klebsiella pneumoniae, E. coli and other bacteria \hyperref[b47]{(44)}. Gram-positive bacteria, meningococcal disease, invasive pneumococcal disease, and group A streptococcal disease are more common when vitamin D levels are low \hyperref[b48]{(45)}. However, the prevalence rate of osteomyelitis reported in this study (3.1\%) is lower than rate reported in the literature (12\%). \hyperref[b41]{(40)}. This means low 25 OHD did not predispose Sudanese children with SCA to osteomyelitis.\par
Vitamin D was found to have a positive effect on erythropoiesis. Therefore vitamin D deficiency is expected to limit erythropoiesis and to increase anemia in patients with anemia of chronic diseases. \hyperref[b49]{(46)} In this study the were no differences in the mean hemoglobin level or requirement of blood transfusion in patients with low level of 25 OHD compared to vitamin D sufficient patients. Winters et al. found no correlation of baseline hemoglobin level and 25 OHD level in either pediatric or adult patients \hyperref[b8]{(9)}. Busse et al. supplemented 50 sickle cell disease patients aged 0 to 21years, who were vitamin D deficient, with vitamin. They studied the association between time-dependent 25 OHD level, hemoglobin concentration, and reticulocyte percentage over time in days. This did not improve the anemia: in fact a reduction in hemoglobin with reticulocytosis was observed with increasing 25-OHD suggesting hemolysis \hyperref[b50]{(47)}. A recent study had shown that Serum 25hydroxyvitamin D correlated with biomarkers of hemolysis in SCD \hyperref[b51]{(48)}. Kaitlyn et al. from Canada found that a 1 g/L increase in hemoglobin concentration was associated with a 0.4 (95\% CI: 0.1-0.8) nmol/L increase in mean serum 25OHD concentration (P = 0.01) \hyperref[b52]{(49)}. Since patients with SCA are prone to low levels of 25 OHD and thus they are likely to receive vitamin D supplementation further studies are needed in this area to determine its safety.\par
High BMI was reported to be associated with low vitamin D level in normal children and adolescent \hyperref[b53]{(50,}\hyperref[b54]{51)}. A similar finding was also observed in young adults with SCA \hyperref[b55]{(52)}. Children with SCA are known to have low BMI \{53). We had a similar finding in this study. However, we failed to demonstrate any difference in BMI between those with low and normal vitamin D level in the study group. 
\section[{V. Conclusion}]{V. Conclusion}\par
A high prevalence rate of vitamin D insufficiency or deficiency in Sudanese children with SCA was found. We could not identify the cause but it is probably multifactorial. Living in a country with enough sun light throughout the year does not guarantee adequate level of vitamin D. Low levels of serum calcium and phosphorus and high alkaline phosphatase can be used as marker of low vitamin D level. Despite low vitamin D level bone fractures were not increased.\par
Study Limitations: Most of the obtained clinical data were recall data which might had led to over or underestimation of the results. The number of children in the control group was small with possibility of overestimation of the prevalence rate of low vitamin D in the study group.\begin{figure}[htbp]
\noindent\textbf{}\includegraphics[]{image-2.png}
\caption{\label{fig_0}F}\end{figure}
  \begin{figure}[htbp]
\noindent\textbf{1} \par 
\begin{longtable}{}
\end{longtable} \par
 
\caption{\label{tab_1}Table 1 :}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{2} \par 
\begin{longtable}{P{0.3070342205323194\textwidth}P{0.3070342205323194\textwidth}P{0.2359315589353612\textwidth}}
Serum Vitamin D Level\tabcellsep Study Group / Frequency (\%)\tabcellsep Control Group / Frequency \%\\
5 -10 ng/Dl\tabcellsep 4 (6.3\%)\tabcellsep 0 (0\%)\\
11 -20 ng/Dl\tabcellsep 8 (12.5)\tabcellsep 0 (0\%)\\
21 -29 ng/Dl\tabcellsep 28 (43.8\%)\tabcellsep 8 (38.1\%)\\
30 -50 ng/Dl\tabcellsep 19 (29.6\%)\tabcellsep 13 (61.9\%)\\
51 -70 ng/Dl\tabcellsep 2 (3.1\%)\tabcellsep \\
71 + ng/Dl\tabcellsep 3 (4.7\%)\tabcellsep \\
Total\tabcellsep 64 (100\%)\tabcellsep 21 (100\%)\end{longtable} \par
 
\caption{\label{tab_2}Table 2 :}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{3} \par 
\begin{longtable}{P{0.16145251396648044\textwidth}P{0.10921787709497206\textwidth}P{0.061731843575419\textwidth}P{0.12821229050279329\textwidth}P{0.08547486033519554\textwidth}P{0.09022346368715084\textwidth}P{0.0712290502793296\textwidth}P{0.05698324022346368\textwidth}P{0.08547486033519554\textwidth}}
Serum Calcium\tabcellsep 25 OHD Deficiency\tabcellsep \%\tabcellsep 25 OHD Insufficiency\tabcellsep \%\tabcellsep Normal 25 OHD\tabcellsep \%\tabcellsep Total\tabcellsep \%\\
<8.6\tabcellsep 11\tabcellsep 91.7\tabcellsep 17\tabcellsep 60.7\tabcellsep 2\tabcellsep 8.3\tabcellsep 30\tabcellsep 46.9\\
8.6-10.3\tabcellsep 1\tabcellsep 8.3\tabcellsep 10\tabcellsep 35.7\tabcellsep 22\tabcellsep 91.7\tabcellsep 33\tabcellsep 51.6\\
10.4\tabcellsep -\tabcellsep -\tabcellsep 1\tabcellsep 3.6\tabcellsep -\tabcellsep -\tabcellsep 1\tabcellsep 1.5\\
Total\tabcellsep 12\tabcellsep 100\tabcellsep 28\tabcellsep 100.0\tabcellsep 24\tabcellsep 100\%\tabcellsep 64\tabcellsep 100.0\end{longtable} \par
 
\caption{\label{tab_4}Table 3 :}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{4} \par 
\begin{longtable}{P{0.4762931034482758\textwidth}P{0.10014367816091953\textwidth}P{0.11235632183908047\textwidth}P{0.07083333333333333\textwidth}P{0.046408045977011494\textwidth}P{0.04396551724137931\textwidth}}
Number\tabcellsep Study Group With Low 25 OHD\tabcellsep Study Group With Normal 25 OHD\tabcellsep P Value\tabcellsep Control Group\tabcellsep P Value\\
Painful Crisis per Patient per Year\tabcellsep 1\tabcellsep 0.95\tabcellsep 0.135\tabcellsep 0\tabcellsep -\\
Number of Hospital Admission for Pain per Year / Patient\tabcellsep 3.3\tabcellsep 2.6\tabcellsep 0.453\tabcellsep 0\tabcellsep -\\
Fractures\tabcellsep 2**\tabcellsep 2*\tabcellsep \tabcellsep 2\tabcellsep 0.179\\
Osteomyelitis\tabcellsep 2\tabcellsep 0\tabcellsep NS\tabcellsep 0\tabcellsep NS\\
Mean Hemoglobin (G/Dl\tabcellsep 6.9\tabcellsep 7.6\tabcellsep 0.132\tabcellsep 0\tabcellsep 0\\
Number of Blood Transfusion\tabcellsep 2.1\tabcellsep 2.7\tabcellsep 0.446\tabcellsep 0\tabcellsep 0\\
**: Caused by osteomyelitis.\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \end{longtable} \par
  {\small\itshape [Note: *: Caused by a fall from one-meter height.]} 
\caption{\label{tab_5}Table 4 :}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{5} \par 
\begin{longtable}{P{0.17246376811594202\textwidth}P{0.11394927536231884\textwidth}P{0.06159420289855073\textwidth}P{0.12934782608695652\textwidth}P{0.07391304347826086\textwidth}P{0.10778985507246377\textwidth}P{0.05543478260869565\textwidth}P{0.043115942028985506\textwidth}P{0.09239130434782608\textwidth}}
BMI Percentile\tabcellsep 25 OHD Deficiency (5-20 ng/Dl)\tabcellsep \%\tabcellsep 25 OHD Insufficiency (21-29 ng/Dl)\tabcellsep \%\tabcellsep Normal 25 OHD (50-70 ng/Dl)\tabcellsep \%\tabcellsep Total\tabcellsep Overall \%\\
<3 rd\tabcellsep 9\tabcellsep 75.0\tabcellsep 16\tabcellsep 57.1\tabcellsep 18\tabcellsep 75\tabcellsep 43\tabcellsep 67.1\\
At 10 th\tabcellsep 2\tabcellsep 16.7\tabcellsep 3\tabcellsep 10.7\tabcellsep 0\tabcellsep 0\tabcellsep 5\tabcellsep 7.8\\
At 25 th\tabcellsep 1\tabcellsep 8.3\tabcellsep 5\tabcellsep 17.9\tabcellsep 4\tabcellsep 16.7\tabcellsep 10\tabcellsep 15.6\\
At 50 th\tabcellsep 0\tabcellsep 0\tabcellsep 4\tabcellsep 14.2\tabcellsep 2\tabcellsep 8.3\tabcellsep 6\tabcellsep 9.3\\
At 75 th\tabcellsep 0\tabcellsep 0\tabcellsep 0\tabcellsep 0\tabcellsep 0\tabcellsep 0\tabcellsep 0\tabcellsep 0\\
Total\tabcellsep 12\tabcellsep 100.0\tabcellsep 28\tabcellsep 100.0\tabcellsep 24\tabcellsep 100.0\tabcellsep 64\tabcellsep 100.0\end{longtable} \par
  {\small\itshape [Note: © 2018 Global Journals 1]} 
\caption{\label{tab_6}Table 5 :}\end{figure}
 		 		\backmatter   			 
\subsection[{Acknowledgments}]{Acknowledgments}\par
We would like to thank DR Khalid Rashid for the critical review of the manuscript and his valuable comments. 			  			  				\begin{bibitemlist}{1}
\bibitem[]{b27}\label{b27} 	 		\textit{},  		 \xref{http://dx.doi.org/10.1002/ajh.2830080406}{10.1002/ajh.2830080406}.  		 \url{https://onlinelibrary.wiley.com/doi/abs/10.1002/ajh.2830080406}  		 	 
\bibitem[Akakpo-Numado et al.]{b43}\label{b43} 	 		\textit{},  		 			G K Akakpo-Numado 		,  		 			K Gnassingbe 		,  		 			M A Boume 		,  		 			B Songne 		,  		 			H Tekou 		.  		 	 	 (Current bacterial causes of osteomyelitis in children with sickle cell disease) 
\bibitem[Health and Nutr (1996)]{b29}\label{b29} 	 		\textit{},  		 			MichealF 		,  		 			Bone Health 		,  		 			Nutr 		.  		 \url{https://www.ncbi.nlm.nih.gov/pubmed/8642450}  		1996 Apr: 125. p. .  	 
\bibitem[ Sante ()]{b44}\label{b44} 	 		\textit{},  	 	 		\textit{Sante}  		2008.  	 
\bibitem[ (Apr-Jun: 18)]{b45}\label{b45} 	 		\textit{},  		 \xref{http://dx.doi.org/10.1684/san.2008.0106}{10.1684/san.2008.0106}.  		Apr-Jun: 18. p. .  	 	 (Article in French) 
\bibitem[ (Mar 8)]{b35}\label{b35} 	 		\textit{},  		 \xref{http://dx.doi.org/10.1080/20469047.2017.1295012?journalCode=ypch20}{10.1080/20469047.2017.1295012?journalCode=ypch20}.  		 \url{https://www.tandfonline.com/doi/abs/10.1080/20469047.2017.1295012?journalCode=ypch20}  		Mar 8.  	 
\bibitem[Raj et al. (2014)]{b31}\label{b31} 	 		\textit{Abnormalities in renal tubular phosphate handling in children with sickle cell disease. Pediatr Blood Cancer},  		 			V M Raj 		,  		 			M Freundlich 		,  		 			D Hamideh 		,  		 			O Alvarez 		,  		 			W Seeherunvong 		,  		 			C Abitbol 		.  		 \xref{http://dx.doi.org/10.1002/pbc.25188}{10.1002/pbc.25188}.  		 \url{https://onlinelibrary.wiley.com/doi/full/10.1002/pbc.25188}  		2014 Dec. 2014 Aug 17. p. .  	 
\bibitem[Neonato et al. (2000)]{b41}\label{b41} 	 		‘Acute clinical events in 299 Homozygous sickle cell disease’.  		 			M Neonato 		,  		 			B Guilloud 		,  		 			P Bequvias 		,  		 			M Maeir 		,  		 			M Belloy 		,  		 			P Bengue 		.  		 \url{https://www.ncbi.nlm.nih.gov/pubmed/11007050}  	 	 		\textit{Eur J Haematol}  		2000 Sep: 65.  (3)  p. .  	 
\bibitem[Shieh and Aloia (2016)]{b4}\label{b4} 	 		‘Assessing Vitamin D Status in African Americans and the Influence of Vitamin D on Skeletal Health Parameters’.  		 			A Shieh 		,  		 			J F Aloia 		.  		 \xref{http://dx.doi.org/10.1016/j.ecl.2016.09.006}{10.1016/j.ecl.2016.09.006}.  		 \url{ttps://www.endo.theclinics.com/article/S0889-8529}  	 	 		\textit{Endocrinol Metab Clin North Am}  		2017 Mar. 2016 Dec 14. 46  (1)  p. .  	 
\bibitem[Pandey et al.]{b30}\label{b30} 	 		‘Biochemical indicator of sickle cell disease: preliminary report from India’.  		 			S Pandey 		,  		 			A Sharma 		,  		 			S Dahia 		,  		 			V Shah 		,  		 			V Sharma 		,  		 			R M Mishra 		.  		 \url{https://link.springer.com/article/10.1007\%2Fs12291-011-0162-y}  	 	 		\textit{Ind J Clin Biochem}  		2012  (2)  p. .  	 
\bibitem[Lal et al. ()]{b19}\label{b19} 	 		‘Bone mineral density in children with sickle cell anemia’.  		 			A Lal 		,  		 			E B Fung 		,  		 			Z Pakbaz 		,  		 			E Hackney-Stephens 		,  		 			E P Vichinsky 		.  		 \url{http://www.bloodjournal.org/content/112/11/4793?sso-checked=true}  	 	 		\textit{Pediatr Blood Cancer}  		2006. 47 p. .  	 
\bibitem[Cooper et al. ()]{b37}\label{b37} 	 		‘Epidemiology of childhood fractures in Britian: a study using the general practice research database’.  		 			C Cooper 		,  		 			E M Dennison 		,  		 			H G M Leufkens 		,  		 			N Bishop 		,  		 			T P Van Staa 		.  		 \url{https://www.ncbi.nlm.nih.gov/pubmed/15537440}  	 	 		\textit{J Bone Min Res}  		2004.  (12)  p. .  	 
\bibitem[Holick et al. ()]{b7}\label{b7} 	 		‘Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline’.  		 			M F Holick 		,  		 			N C Binkley 		,  		 			H A Bischoff-Ferrari 		,  		 			C M Gordon 		,  		 			D A Hanley 		,  		 			R P Heaney 		,  		 			M H Murad 		,  		 			C M Weaver 		.  		 \xref{http://dx.doi.org/10.1210/jc.2011-0385}{10.1210/jc.2011-0385}.  		 \url{https://doi.org/10.1210/jc.2011-0385}  	 	 		\textit{J Clin Endocrinol Metab}  		2011.  (7)  p. .  	 
\bibitem[Fung et al. ()]{b39}\label{b39} 	 		‘Fracture prevalence and relationship to endo crinopathy in iron overloaded patients with sickle cell disease and thalassemia’.  		 			E B Fung 		,  		 			P R Harmatz 		,  		 			M Milet 		,  		 			T D Coates 		,  		 			A A Thompson 		,  		 			M Ranalli 		.  	 	 		\textit{Bone}  		2008. 43 p. .  	 
\bibitem[Aloia et al. (2015)]{b5}\label{b5} 	 		‘Free 25 (OH)D and the Vitamin D Paradox in African Americans’.  		 			J Aloia 		,  		 			M Mikhail 		,  		 			R Dhaliwal 		,  		 			A Shieh 		,  		 			G Usera 		,  		 			A Stolberg 		,  		 			L Ragolia 		,  		 			S Islam 		.  		 \xref{http://dx.doi.org/10.1210/JC.2015-2066}{10.1210/JC.2015-2066}.  		 \url{https://academic.oup.com/jcem/article-lookup/doi/10.1210/JC.2015-2066}  	 	 		\textit{J Clin Endocrinol Metab}  		2015 Sep. 2015 Jul 10. 100  (9)  p. .  	 
\bibitem[Ozen et al. ()]{b12}\label{b12} 	 		‘Frequency and risk factors of endocrine complications in Turkish children and adolescents with sickle cell anemia’.  		 			S Ozen 		,  		 			S Unal 		,  		 			N Ercetin 		,  		 			B Tasdelen 		.  		 \xref{http://dx.doi.org/10.4274/tjh.2012.0001}{10.4274/tjh.2012.0001}.  		 \url{https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3781645/}  	 	 		\textit{Turk J Haematol}  		2013. 30 p. .  	 
\bibitem[Osunkwo et al. ()]{b15}\label{b15} 	 		‘High dose vitamin D therapy for chronic pain in children and adolescents with sickle cell disease: results of a randomized double blind pilot study’.  		 			I Osunkwo 		,  		 			T R Ziegler 		,  		 			J Alvarez 		,  		 			C Mccracken 		,  		 			K Cherry 		,  		 			C E Osunkwo 		.  		 \url{https://www.ncbi.nlm.nih.gov/pubmed/22924607}  	 	 		\textit{Br J Haematol}  		2012. 159 p. 211.  	 
\bibitem[Rovner et al. (2008)]{b13}\label{b13} 	 		‘High risk of vitamin D deficiency in children with sickle cell disease’.  		 			A J Rovner 		,  		 			V A Stallings 		,  		 			D A Kawchak 		,  		 			J I Schall 		,  		 			K Ohene-Frempong 		,  		 			B S Zemel 		.  		 \url{https://www.sciencedirect.com/science/article/pii/S0002822308012637}  	 	 		\textit{J Am Diet Assoc}  		2008 Sep. 108  (9)  p. 1512.  	 
\bibitem[Luthra and Sears (1982)]{b28}\label{b28} 	 		‘Increased Ca++, Mg++, and Na+ + K+ ATPase activities in erythrocytes of sickle cell anemia’.  		 			M G Luthra 		,  		 			D Sears 		.  		 \url{http://www.bloodjournal.org/content/bloodjournal/60/6/1332.full.pdf?sso-checked=true}  	 	 		\textit{Blood}  		1982 Dec.  (6)  p. .  	 
\bibitem[Adegoke et al. ()]{b34}\label{b34} 	 		\textit{Influence of serum 25-hydroxyvitamin D on the rate of pain episodes in Nigerian children with sickle cell anaemia. Paediatr Int Child Health},  		 			S A Adegoke 		,  		 			O A Oyelami 		,  		 			A Adekile 		,  		 			M Figueiredo 		.  		 \xref{http://dx.doi.org/10.1080/20469047.2017.1295012}{10.1080/20469047.2017.1295012}.  		2017 Aug: 37. 2017. p. .  	 
\bibitem[Crowle et al. ()]{b47}\label{b47} 	 		‘Inhibition by 1, 25 (OH) 2-vitamin D3 of the multiplication of virulent tubercle bacilli in cultured human macrophages’.  		 			A J Crowle 		,  		 			E J Ross 		,  		 			M H May 		.  		 \url{https://www.ncbi.nlm.nih.gov/pmc/articles/PMC260011/}  	 	 		\textit{Infect Immun}  		1987. 55 p. .  	 	 (PMC free article) 
\bibitem[Dong et al. ()]{b53}\label{b53} 	 		‘Low 25 OHD level in adolescent: race, season, adiposity and fatness’.  		 			V Dong 		,  		 			N Pollock 		,  		 			J Stallman 		,  		 			I S Orgen 		,  		 			D Keeton 		,  		 			K Pottty 		.  		 \url{http://pediatrics.aappublications.org/content/pediatrics/early/2010/05/03/peds.2009-2055.full.pdf}  	 	 		\textit{Peadiatrics}  		2010. 125 p. .  	 
\bibitem[Buison et al. (2004)]{b3}\label{b3} 	 		‘Low vitamin D status in children with sickle cell disease’.  		 			A Buison 		,  		 			D Kawchak 		,  		 			J Schall 		,  		 			F Ohene 		,  		 			V Stalling 		,  		 			B Zemel 		.  		 \xref{http://dx.doi.org/10.1016/j.jpeds.2004.06.055}{10.1016/j.jpeds.2004.06.055}.  	 	 		\textit{J Pediatr}  		2004 Nov: 145.  (5)  p. .  	 
\bibitem[Fung et al. ()]{b56}\label{b56} 	 		‘Marker of bone turn over associated with growth and development in young subject with sickle cell anemia’.  		 			E Fung 		,  		 			D Kawahak 		,  		 			B Zemel 		,  		 			A Rovner 		,  		 			F Ohene 		,  		 			V Stalling 		.  		 \url{https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2561913/}  	 	 		\textit{Pediatr Blood Cancer}  		2008. 50 p. .  	 
\bibitem[Oladipo et al.]{b22}\label{b22} 	 		‘Obomanu Serum magnesium, phosphate and calcium in Nigerian children with sickle cell disease’.  		 			O Oladipo 		,  		 			O Temiye 		,  		 			C Ezeaka 		.  		 \url{https://www.researchgate.net/publication/7668718}  	 	 		\textit{WAJM}  		2005  (2)  p. .  	 
\bibitem[Dallal ()]{b46}\label{b46} 	 		‘Osteomyelitis: A manifestation of sickle cell anemia’.  		 			Al Dallal 		,  		 			SM 		.  		 \xref{http://dx.doi.org/10.15761/CMI.1000132}{10.15761/CMI.1000132}.  		 \url{http://www.oatext.com/Osteomyelitis-A-manifestation-of-sickle-cell-anemia.php}  	 	 		\textit{Clin Med Invest}  		2017.  	 
\bibitem[Chapelon et al. ()]{b18}\label{b18} 	 		‘Osteopenia and vitamin D deficiency in children with sickle cell disease’.  		 			E Chapelon 		,  		 			M Garabedian 		,  		 			V Brousse 		,  		 			J C Souberbielle 		,  		 			J L Bresson 		,  		 			M De Montalembert 		.  		 \url{https://www.ncbi.nlm.nih.gov/pubmed/19682065}  	 	 		\textit{Eur J Haematol}  		2009. 83 p. .  	 
\bibitem[Hassan et al. (2013)]{b55}\label{b55} 	 		\textit{Prevalence of vitamin D deficiency in patients with sickle cell disease in Bahrain},  		 			A Hassan 		,  		 			T Garadah 		,  		 			A Jaradadat 		,  		 			Al Ajmi 		,  		 			A Alawi 		,  		 			M Sequeira 		,  		 			R 		.  		 \url{https://www.sciencepubco.com/index.php/IJM/article/view/1126}  		Aug. 2013.  	 	 (IJM, v. 1, n. 2, P. 23-28) 
\bibitem[Samson et al. (2018)]{b52}\label{b52} 	 		‘Prevalence of Vitamin D Deficiency Varies Widely by Season in Canadian Children and Adolescents with Sickle Cell Disease’.  		 			K L Samson 		,  		 			H Mccartney 		,  		 			S M Vercauteren 		,  		 			J K Wu 		,  		 			C D Karakochuk 		.  		 \xref{http://dx.doi.org/10.3390/jcm7020014}{10.3390/jcm7020014}.  		 \url{https://www.ncbi.nlm.nih.gov/pubmed/29385701}  	 	 		\textit{J Clin Med}  		2018 Jan 30.  (2)  p. 7.  	 
\bibitem[Ryan et al.]{b42}\label{b42} 	 		‘Prevalence of vitamin D insufficiency in African American children with forearm fractures: a preliminary study’.  		 			L M Ryan 		,  		 			C Brandoli 		,  		 			R J Freishtat 		,  		 			J L Wright 		,  		 			L Tosi 		,  		 			J M Chamberlain 		.  		 \xref{http://dx.doi.org/10.1302/1863-2548.11.160008}{10.1302/1863-2548.11.160008}.  		 \url{https://online.boneandjoint.org.uk/doi/pdf/10.1302/1863-2548.11.160008}  	 	 		\textit{J Pediatr Orthop}  		2010  (2)  p. .  	 
\bibitem[Smotkin et al. ()]{b54}\label{b54} 	 		‘Prevalence of vitamin D insufficiency in obese child and adolescent’.  		 			T M Smotkin 		,  		 			R Purushothman 		,  		 			A Gupta 		,  		 			G Nejati 		,  		 			H An 		,  		 			S Ten 		.  	 	 		\textit{J Pediatr Endocrinol Metab}  		2007. 2017. p. 92.  	 
\bibitem[Al-Dabbagh et al. ()]{b25}\label{b25} 	 		‘Radiological bone changes of sickle cell anaemia in Western Saudi Arabia’.  		 			A A Al-Dabbagh 		,  		 			J K Acquaye 		,  		 			T M Al-Baghdadai 		,  		 			M Elzamzamy 		.  	 	 		\textit{Saudi Med J}  		1989. 10 p. .  	 
\bibitem[Al-Harbi et al. ()]{b32}\label{b32} 	 		‘Renal Reabsorption of Phosphate in Children with Sickle Cell Anemia’.  		 			N Al-Harbi 		,  		 			S H Annobil 		,  		 			F Abbag 		,  		 			F Adzaku 		,  		 			W Bassuni 		.  		 \xref{http://dx.doi.org/10.1159/000013518}{10.1159/000013518}.  	 	 		\textit{Am J Nephrol}  		1999. 19 p. .  	 
\bibitem[Nduka and Ekeke ()]{b24}\label{b24} 	 		‘Serum calcium and protein in haemoglobin-SS patients’.  		 			N Nduka 		,  		 			G I Ekeke 		.  	 	 		\textit{Folia Haematol}  		1987. 114 p. .  	 
\bibitem[Van Der Dijs et al. ()]{b17}\label{b17} 	 		‘Serum calcium and vitamin D status of patients with sickle cell disease in Curaçao’.  		 			F P Van Der Dijs 		,  		 			F R Van Der Klis 		,  		 			F D Muskiet 		,  		 			F A Muskiet 		.  		 \url{https://www.ncbi.nlm.nih.gov/pubmed/9133251}  	 	 		\textit{Ann Clin Biochem}  		1997. 34 p. .  	 
\bibitem[Mohammed et al. ()]{b14}\label{b14} 	 		‘Serum calcium, parathyroid hormone, and vitamin D status in children and young adults with sickle cell disease’.  		 			S Mohammed 		,  		 			S Addae 		,  		 			S Suleiman 		,  		 			F Adzaku 		,  		 			S Annobil 		,  		 			O Kaddoumi 		.  	 	 		\textit{Ann Clin Biochem}  		1993. 1 p. .  	 	 (Pt) 
\bibitem[Martin ()]{b0}\label{b0} 	 		‘Sickle cell anemia, the first molecular disease: over view of molecular etiology, pathophysiology and therapeutic approach’.  		 			H Martin 		.  		 \xref{http://dx.doi.org/10.1100/tsw.2008.157www.ncbi.nlm.nih.gov/pubmed/19112541}{10.1100/tsw.2008.157www.ncbi.nlm.nih.gov/pubmed/19112541}.  		 \url{doi:10.1100/tsw.2008.157www.ncbi.nlm.nih.gov/pubmed/19112541}  	 	 		\textit{TSW J}  		2008.  (8)  p. .  	 
\bibitem[Schnog et al. (2004)]{b1}\label{b1} 	 		‘Sickle cell disease: general overview’.  		 			J B Schnog 		,  		 			A J Duits 		,  		 			F A Muskiet 		,  		 			H Cate 		,  		 			R A Rojer 		,  		 			D P Brandjes 		.  		 \url{https://www.ncbi.nlm.nih.gov/pubmed/15683091}  	 	 		\textit{Neth J Med}  		2004 Nov: 62.  (10)  p. .  	 
\bibitem[Jaiyesimi et al. (2002)]{b40}\label{b40} 	 		‘Sickle cell morbidity profile in Omani children’.  		 			F Jaiyesimi 		,  		 			R Pandey 		,  		 			D Bux 		,  		 			Y Sreekrishna 		,  		 			F Zaki 		,  		 			N Krishnamoorthy 		.  		 \url{https://www.ncbi.nlm.nih.gov/pubmed/11926049}  	 	 		\textit{Ann Trop Paediatr}  		2002 Mar: 22.  (1)  p. .  	 
\bibitem[Litosch and Lee ()]{b26}\label{b26} 	 		‘Sickle red cell calcium metabolism: studies on Ca2+-Mg2+ATPase and Ca-binding properties of sickle red cell membranes’.  		 			I Litosch 		,  		 			K S Lee 		.  	 	 		\textit{Am J Hematol}  		1980. 8  (4)  p. .  	 
\bibitem[Garrido et al. ()]{b11}\label{b11} 	 		‘Status of vitamin D in children with sickle cell disease living in Madrid, Spain’.  		 			C Garrido 		,  		 			E Cela 		,  		 			C Belendez 		,  		 			C Mata 		,  		 			J Huerta 		.  		 \xref{http://dx.doi.org/10.1007/s00431-012-1817-2}{10.1007/s00431-012-1817-2}.  		 \url{https://link.springer.com/article/10.1007/s00431-012-1817-2}  	 	 		\textit{Eur J Pediatr}  		2012. 171 p. .  	 
\bibitem[Aldallal]{b9}\label{b9} 	 		‘status of vitamin D in Sickle cell Disease: A study of one capital area in Kuwait’.  		 			S Aldallal 		.  	 	 		\textit{IJIRR}  		2  (16)  p. .  	 
\bibitem[Holick ()]{b6}\label{b6} 	 		‘Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease’.  		 			M F Holick 		.  		 \url{https://www.ncbi.nlm.nih.gov/pubmed/15585788}  	 	 		\textit{Am J Clin Nutr}  		2004. 80 p. .  	 
\bibitem[Wacker and Holick (2013)]{b20}\label{b20} 	 		‘Sunlight and Vitamin D: A global perspective for health’.  		 			Matthias Wacker 		,  		 			Michael F Holick 		.  		 doi: 10.4161.  	 	 		\textit{Dermatoendocrinol}  		2013 Jan 1. 2013 Jan 1. 5  (1)  p. .  	 	 (Published online) 
\bibitem[Adegoke et al. (2018)]{b51}\label{b51} 	 		‘The Association of Serum 25-Hydroxyvitamin D With Biomarkers of Hemolysis in Pediatric Patients With Sickle Cell Disease’.  		 			S A Adegoke 		,  		 			J A P Braga 		,  		 			A D Adekile 		,  		 			M S Figueiredo 		.  		 \xref{http://dx.doi.org/10.1097/MPH.0000000000000783}{10.1097/MPH.0000000000000783}.  		 \url{https://app.dimensions.ai/details/publication/pub.1024902337}  	 	 		\textit{J Pediatr Hematol.Oncol}  		2018 Mar: 40.  (2)  p. .  	 
\bibitem[Sabahelzain and Hamamy (2014)]{b2}\label{b2} 	 		‘The ethnic distribution of sickle cell disease in Sudan’.  		 			M Sabahelzain 		,  		 			H Hamamy 		.  		 \xref{http://dx.doi.org/10.11604/pamj.2014.18.13.3280}{10.11604/pamj.2014.18.13.3280}.  		 \url{www.ncbi.nlm.nih.gov/pmc/articles/PMC4213521/}  	 	 		\textit{Pan Afr Med J}  		2014. 2014 May 3.  	 	 (Published online) 
\bibitem[Nduka et al. (1995)]{b23}\label{b23} 	 		‘Variation in serum electrolytes and enzyme concentrations in patients with sickle cell disease’.  		 			N Nduka 		,  		 			Y Kazem 		,  		 			B Saleh 		.  		 \url{https://www.ncbi.nlm.nih.gov/pmc/articles/PMC502717/}  	 	 		\textit{J Clin Pathol}  		1995 Jul: 48.  (7)  p. .  	 
\bibitem[Lee et al. (2015)]{b36}\label{b36} 	 		\textit{Vitamin D deficiency and acute vaso-occlusive complications in children with sickle cell disease. Pediatr Blood Cancer},  		 			M T Lee 		,  		 			M Licursi 		,  		 			D J Mcmahon 		.  		 \xref{http://dx.doi.org/10.1002/pbc.25399}{10.1002/pbc.25399}.  		 \url{https://www.researchgate.net/publication/27091809}  		2015 Apr: 62. 2015 Jan 13. p. .  	 
\bibitem[Uwaezuoke (2017)]{b49}\label{b49} 	 		‘Vitamin D deficiency and anemia risk in children: a review of emerging evidence’.  		 			S N Uwaezuoke 		.  		 \xref{http://dx.doi.org/10.2147/PHMT.S129362}{10.2147/PHMT.S129362}.  		 \url{https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5774601/}  	 	 		\textit{Pediatric Health Med Ther}  		2017 May 10. 2017. 8 p. .  	 
\bibitem[Osunkwo et al. ()]{b16}\label{b16} 	 		‘Vitamin D deficiency and chronic pain in sickle cell disease’.  		 			I Osunkwo 		,  		 			E I Hodgman 		,  		 			K Cherry 		,  		 			C Dampier 		,  		 			J Eckman 		,  		 			T R Ziegler 		.  		 \xref{http://dx.doi.org/10.1111/bjh.12019}{10.1111/bjh.12019}.  		 \url{https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.12019}  	 	 		\textit{Br J Haematol}  		2011. 153 p. .  	 
\bibitem[Jackson et al. ()]{b10}\label{b10} 	 		‘Vitamin D deficiency and comorbidities in children with sickle cell anemia’.  		 			T C Jackson 		,  		 			M J Krauss 		,  		 			M R Debaun 		,  		 			R C Strunk 		,  		 			A M Arbelaez 		.  		 \xref{http://dx.doi.org/10.3109/08880018.2012.661034}{10.3109/08880018.2012.661034}.  		 \url{https://www.ncbi.nlm.nih.gov/pubmed/22475302}  	 	 		\textit{Pediatr Hematol Oncol}  		2012. 29 p. .  	 
\bibitem[Wykes et al. (2014)]{b33}\label{b33} 	 		‘Vitamin D deficiency and its correction in children with sickle cell anaemia’.  		 			C Wykes 		,  		 			A Arasaretnam 		,  		 			S O'driscoll 		,  		 			L Farnham 		,  		 			C Moniz 		,  		 			D C Rees 		.  		 \xref{http://dx.doi.org/10.1007/s00277-014-2144-7}{10.1007/s00277-014-2144-7}.  		 \url{https://link.springer.com/article/10.1007/s00277-014-2144-7}  	 	 		\textit{Ann Hematol}  		2014 Dec. 2014 Jul 2.  (12)  p. .  	 
\bibitem[Winters et al. ()]{b8}\label{b8} 	 		‘Vitamin D Insufficiency is a Frequent Finding in Pediatric and Adult Patients with Sickle Cell Disease and Correlates with Markers of Cell Turnover’.  		 			A C Winters 		,  		 			W Kethman 		,  		 			R Kruse-Jarres 		,  		 			J Kanter 		.  		 \xref{http://dx.doi.org/10.4172/2161-0509.1000140}{10.4172/2161-0509.1000140}.  	 	 		\textit{J Nutr Disorders Ther}  		2014. 4 p. 140.  	 
\bibitem[Busse et al.]{b50}\label{b50} 	 		‘Vitamin D level and its coorelation with Hemoglobin in pediatric sickle cell disease’.  		 			J A Busse 		,  		 			K N Seelaboyina 		,  		 			G Malonga 		,  		 			M J Setty 		,  		 			T Moulton 		.  	 	 		\textit{Blood J. H}  		2013  (21)  p. .  	 
\bibitem[Hanan et al.]{b38}\label{b38} 	 		‘Vitamin D receptor polymorphism indices of bone turn over and bone mass in Egyptian children with sickle cell disease’.  		 			M Hanan 		,  		 			G Ashraf 		,  		 			A Khaled 		,  		 			A Eman 		,  		 			G Ayman 		,  		 			K Rashaa 		.  		 \url{https://www.researchgate.net/publication/228365799}  	 	 		\textit{Res J Med Sci}  		2010  (1)  p. .  	 
\bibitem[Johnson et al. ()]{b21}\label{b21} 	 		‘Vitamin D status: United States’.  		 			Anne C Johnson 		,  		 			M David 		,  		 			A Christine 		,  		 			M Christopher 		,  		 			T 		.  		 \url{https://www.cdc.gov/nchs/data/databriefs/db59.pdf}  	 	 		\textit{NCHS}  		2001-2006. March 2011 Mar. 59 p. .  	 
\bibitem[Rook et al. ()]{b48}\label{b48} 	 		‘Vitamin D3, gamma interferon and control of proliferation of Mycobacterium tuberculosis by human monocytes’.  		 			G A Rook 		,  		 			J Steele 		,  		 			L Fraher 		,  		 			S Barker 		,  		 			R Karmali 		,  		 			J O'riordan 		.  	 	 		\textit{Immunology}  		1986. 57 p. .  	 	 (PMC free article. PubMed) 
\end{bibitemlist}
 			 		 	 
\end{document}
